Literature DB >> 20817099

A new tagged-TEV protease: construction, optimisation of production, purification and test activity.

Baligh Miladi1, Hassib Bouallagui, Cyrine Dridi, Ahmed El Marjou, Guilhem Boeuf, Patrick Di Martino, Florence Dufour, Abdellatif Elm'Selmi.   

Abstract

The Tobacco Etch Virus (TEV) protease is frequently used in the cleavage of recombinant fusion proteins because of its efficiency and high specificity. In this work, we present a new recombinant form of TEV termed Streptag II-TEV for high-level production and purification of TEV protease from Escherichia coli and compare it to the hexahistidine (6xHis) tagged version of TEV. The effects of varying the host strain, the bacterial induction temperature (25, 30 and 37°C) and the IPTG inducer concentration on production and solubility of the two recombinant TEV proteases have been examined. Optimal Streptag II-TEV protein expression were obtained in the E. coli KRX strain under an induction temperature of 25°C in the presence of IPTG at 0.5 mM. In these conditions, soluble Streptag II-TEV and 6xHis-TEV proteases accounted for about 25% and 18% of total soluble proteins, respectively. About 70% of Streptag II-TEV and 60% of 6xHis-TEV were detected in the supernatant. Streptag II-TEV protease purifies to near homogeneity (approximately 99%) via a simple, single step Strep-Tactin chromatography purification protocol based on the presence of Streptag II. The higher production of Streptag II-TEV coupled to its purification and cleavage efficiencies make it an attractive alternate to 6xHis-TEV.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20817099     DOI: 10.1016/j.pep.2010.08.012

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  7 in total

1.  A fusion-protein approach enabling mammalian cell production of tumor targeting protein domains for therapeutic development.

Authors:  Jia Hu; Xiang Chen; Xuhua Zhang; Xiaopeng Yuan; Mingjuan Yang; Hui Dai; Wei Yang; Qinghua Zhou; Weihong Wen; Qirui Wang; Weijun Qin; Aizhi Zhao
Journal:  Protein Sci       Date:  2018-04-14       Impact factor: 6.725

Review 2.  Improved yield, stability, and cleavage reaction of a novel tobacco etch virus protease mutant.

Authors:  Sergio Enríquez-Flores; José Ignacio De la Mora-De la Mora; Luis Antonio Flores-López; Nallely Cabrera; Cynthia Fernández-Lainez; Gloria Hernández-Alcántara; Carlos Enrique Guerrero-Beltrán; Gabriel López-Velázquez; Itzhel García-Torres
Journal:  Appl Microbiol Biotechnol       Date:  2022-01-29       Impact factor: 4.813

3.  Functional evolution of ribonuclease inhibitor: insights from birds and reptiles.

Authors:  Jo E Lomax; Christopher M Bianchetti; Aram Chang; George N Phillips; Brian G Fox; Ronald T Raines
Journal:  J Mol Biol       Date:  2014-06-15       Impact factor: 5.469

4.  An improved strategy for easy process monitoring and advanced purification of recombinant proteins.

Authors:  Baligh Miladi; Cyrine Dridi; Ahmed El Marjou; Guilhem Boeuf; Hassib Bouallagui; Florence Dufour; Patrick Di Martino; Abdellatif Elm'selmi
Journal:  Mol Biotechnol       Date:  2013-11       Impact factor: 2.695

Review 5.  An overview of enzymatic reagents for the removal of affinity tags.

Authors:  David S Waugh
Journal:  Protein Expr Purif       Date:  2011-08-19       Impact factor: 1.650

6.  Rational design of a new mutant of tobacco etch virus protease in order to increase the in vitro solubility.

Authors:  Hossein Mohammadian; Karim Mahnam; Hamid Mirmohammad Sadeghi; Mohamad Reza Ganjalikhany; Vajihe Akbari
Journal:  Res Pharm Sci       Date:  2020-05-11

7.  Optimization of solvent media to solubilize TEV protease using response surface method.

Authors:  Niloufar Mohammadian; Hossein Mohammadian; Fatemeh Moazen; Mohammad Hosein Pakdel; Ali Jahanian-Najafabadi; Hamid Mir Mohammad Sadeghi
Journal:  Res Pharm Sci       Date:  2020-08-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.